Lv3
310 积分 2024-10-13 加入
THE RISKS OF SYSTEMIC CORTICOSTEROID USE
3个月前
已完结
Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function
3个月前
已关闭
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3个月前
已完结
Advances in Locoregional and Systemic Treatments for HCC
3个月前
已完结
Evaluating the Safety and Efficacy of Adding Liver-Directed Radiation Therapy to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma
3个月前
已关闭
Letter: Hepatotoxicity in Malignancies Under ICIs Treatment
4个月前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
4个月前
已完结
Hepatic sinusoidal obstruction syndrome after immune-checkpoint-inhibitor therapy: when the liver sends SOS
4个月前
已完结
Outcomes of immune checkpoint inhibitor‐induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team
4个月前
已完结
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
4个月前
已完结
皖公网安备34019202002308
